Jennifer Brigitte Green, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3850, Durham, NC 27715
Phone (919) 668-8725
Email address green094@mc.duke.edu

Diabetes Mellitus: Prevention strategies, predictors, treatment effects, and cardiovascular outcomes
Thyroid Disease
Bone and Calcium Disorders

Education and Training

  • M.D., University of Virginia, 1993

Publications

Sharma, A, Green, JB, Dunning, A, Lokhnygina, Y, Al-Khatib, SM, Lopes, RD, Buse, JB, Lachin, JM, Van de Werf, F, Armstrong, PW, Kaufman, KD, Standl, E, Chan, JCN, Distiller, LA, Scott, R, Peterson, ED, Holman, RR, and TECOS Study Group, . "Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial." Diabetes care 40, no. 12 (December 2017): 1763-1770.

PMID
28986504
Full Text

Butler, J, Hamo, CE, Filippatos, G, Pocock, SJ, Bernstein, RA, Brueckmann, M, Cheung, AK, George, JT, Green, JB, Januzzi, JL, Kaul, S, Lam, CSP, Lip, GYH, Marx, N, McCullough, PA, Mehta, CR, Ponikowski, P, Rosenstock, J, Sattar, N, Salsali, A, Scirica, BM, Shah, SJ, Tsutsui, H, Verma, S, Wanner, C, Woerle, H-J, Zannad, F, Anker, SD, and EMPEROR Trials Program, . "The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors." European journal of heart failure 19, no. 11 (November 2017): 1390-1400. (Review)

PMID
28836359
Full Text

Navar, AM, Gallup, DS, Lokhnygina, Y, Green, JB, McGuire, DK, Armstrong, PW, Buse, JB, Engel, SS, Lachin, JM, Standl, E, Van de Werf, F, Holman, RR, Peterson, ED, and TECOS Study Group, . "Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin." Hypertension (Dallas, Tex. : 1979) 70, no. 5 (November 2017): 907-914.

PMID
28847886
Full Text

Paul, S, Green, JB, Atherton, J, and Montvida, O. "Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence." September 2017.

Scholars@Duke

Pagidipati, NJ, Navar, AM, Pieper, KS, Green, JB, Bethel, MA, Armstrong, PW, Josse, RG, McGuire, DK, Lokhnygina, Y, Cornel, JH, Halvorsen, S, Strandberg, TE, Delibasi, T, Holman, RR, Peterson, ED, and TECOS Study Group, . "Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)." Circulation 136, no. 13 (September 2017): 1193-1203.

PMID
28626088
Full Text

Herbst, R, Bolton, W, Shariff, A, and Green, JB. "Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions." Current diabetes reports 17, no. 9 (September 2017): 67-. (Review)

PMID
28726152
Full Text

Gray, AM, Leal, J, Reed, SD, Li, Y, Graham, F, Green, JB, Kaufman, KD, Radican, L, Alfredsson, J, Buse, J, Riefflin, A, Van de Werf, F, Peterson, ED, and Holman, RR. "Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)." September 2017.

Scholars@Duke

Engel, SS, Bethel, MA, Garg, J, Stevens, SR, Lokhnygina, Y, Josse, RG, Green, JB, Peterson, ED, Holman, RR, and Grp, TECOSS. "Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)." September 2017.

Scholars@Duke

Bethel, MA, Engel, SS, Green, JB, Huang, Z, Josse, RG, Kaufman, KD, Standl, E, Suryawanshi, S, Van de Werf, F, McGuire, DK, Peterson, ED, Holman, RR, and TECOS Study Group, . "Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)." Diabetes care 40, no. 4 (April 2017): 494-501.

PMID
28057693
Full Text

Bethel, MA, Engel, SS, Green, JB, Huang, Z, Josse, RG, Kaufman, KD, Standl, E, Suryawanshi, S, Van de Werf, F, McGuire, DK, Peterson, ED, Holman, RR, and Grp, TECOSS. "Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)." DIABETES CARE 40, no. 4 (April 2017): 494-501.

Full Text

Pages